Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cancer Genetics Inc Announces Pricing of Public Offering of 1,500,000 Shares of Common Stock


Tuesday, 13 Aug 2013 07:29pm EDT 

Cancer Genetics Inc announced the pricing of its public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. The Company intends to use the net proceeds from the offering to expand sales and marketing, to further product commercialization, to invest in its Mayo Clinic joint venture, to retire mezzanine financing, to continue research and development, and to fund other general working capital needs. Aegis Capital Corp. is acting as sole book-running manager for the offering. Feltl and Company, Inc. is acting as co-lead manager for the offering. 

Company Quote

10.2
0.02 +0.20%
11 Jul 2014